MedTrace Logo

Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.

NCT07524140 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-13

No results posted yet for this study

Summary

Phase 1 Study of ZE94-0605 in solid tumors who have exhausted all treatment options and then with expansion into two dose cohorts in select solid tumor patients.

Conditions

  • Solid Tumor Malignancies
  • Solid Cancer
  • Metastatic Solid Tumor

Interventions

DRUG

ZE94-0605

Oral capsules QD

Sponsors & Collaborators

  • Eilean Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2028-01-31
Completion
2028-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07524140 on ClinicalTrials.gov